Abstract
Alcohol use disorder (AUD) commonly co-occurs with posttraumatic stress disorder (PTSD), and comorbid PTSD and AUD is associated with poorer outcomes including worse treatment outcomes and significant physical health consequences. Both PTSD and AUD are polygenic in nature and genetically overlap. Previous work showed negative or non-significant associations between PTSD and alcohol consumption but positive genetic associations between PTSD and AUD. This work highlights the need for more nuanced examination of the similarities and distinctions in the associations between PTSD and alcohol consumption versus AUD. We leveraged the latest large-scale GWAS data to perform a multivariate GWAS of alcohol consumption (ALCC), problematic alcohol use (ALCP), and PTSD using GenomicSEM. Partial genetic correlations revealed that ALCP and PTSD were associated with each other (rG=0.39, p = 4.38×10-60) and with other psychiatric problems, medical conditions, and pain, while ALCC was generally only weakly correlated with PTSD (rG=-0.08, p = 2.03×10-4) and uncorrelated with most traits after accounting for its genetic overlap with ALCP and PTSD. We examined associations between GenomicSEM-derived polygenic scores (PGS) and their corresponding phenotypes in participants from the Collaborative Study on the Genetics of Alcoholism (COGA). PGS for ALCC were unrelated to PTSD diagnosis and PGS for PTSD were unrelated to drinks in a typical week. PTSD is more strongly related to alcohol problems, and much of the overlap in PTSD and consumption is accounted for by its overlap with alcohol problems. These results help demonstrate the complex partial overlaps of PTSD, AUD, and alcohol consumption.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported in part by the National Institute of Drug Abuse (R01DA060596, R01DA054138), and the National Institute on Alcohol Abuse and Alcoholism (U10AA008401, R01AA030549), and NIMH R01MH106595. AA was additionally supported by R01DA054869. KB was supported by K01AA028058 and R34DA061267. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the IRBs of SUNY Downstate and Virginia Commonwealth University.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† These authors jointly supervised to this work
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.